Picard Medical, Inc.
Picard Medical, Inc. (NYSE American: PMDQ) operates as a holding company that owns SynCardia Systems, LLC, a medical technology company focused on manufacturing and commercializing the SynCardia Total Artificial Heart, the only FDA and Health Canada approved total artificial heart available for commercial use in North… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Picard Medical, Inc. does
In the company’s own words
Picard Medical, Inc. (NYSE American: PMDQ) operates as a holding company that owns SynCardia Systems, LLC, a medical technology company focused on manufacturing and commercializing the SynCardia Total Artificial Heart, the only FDA and Health Canada approved total artificial heart available for commercial use in North America. The company's website is www.syncardia.com.
SynCardia's core product, the SynCardia TAH, is a biventricular replacement device that fully replaces the function of a failing human heart by replacing both ventricles and all four heart valves. The device consists of an implant with left and right artificial ventricles, external pneumatic drivers that power the implant, and drivelines connecting the external driver to the implant. The system generates pulsatile flow with cardiac output up to 10.5 liters per minute for the 70cc implant and 7.5 liters per minute for the 50cc implant. To date, more than 2,100 SynCardia TAHs have been implanted across 27 countries, establishing the device as an established bridge to heart transplantation for patients with end-stage biventricular heart failure.
The SynCardia TAH received FDA premarket approval in 2004 and Health Canada approval in 2005 for use as a bridge to transplantation. The company offers two external driver systems: the Companion 2 Driver for in-hospital use, approved by the FDA in 2012, and the Freedom Driver for portable home use, approved in 2014. Both drivers connect to the implant via drivelines and deliver precisely calibrated air pulses to operate the artificial ventricles.
The company completed its initial public offering in September 2025, raising approximately $15.2 million in net proceeds. Picard Medical is pursuing multiple growth initiatives including development of the Emperor TAH, a next-generation fully implantable artificial heart designed to eliminate external pneumatic drivers, with potential FDA approval targeted as early as 2028. The company is also developing the Unicorn driver system to improve portability and patient quality of life, and seeking expanded indications for the SynCardia TAH including bridge to candidacy and longer-term support. Additionally, Picard is pursuing regulatory approvals in select international markets including the European Union and China.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- TUCSON, AZ
- Fiscal year end
- December
- CIK
- 2030617
- SIC
- 3841
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Picard Medical, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Picard Medical, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Picard Medical, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Picard Medical, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Picard Medical, Inc.'s last four quarterly filings that the numbers alone won't show?”